Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096843 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
A Phase 2 study of Primary Membranous Nephropathy, sponsored by Climb Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT07096843 is a Phase 2 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Climb Bio. The registered enrollment target is 45 participants, below the 131-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT07096843, a Phase 2 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Climb Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Conditions Studied
Interventions
- DRUG budoprutug
Study Locations (20)
Other
- Climb Bio Investigative Site# 602 - Buenos Aires
- Climb Bio Investigative Site# 603 - Buenos Aires
- Climb Bio Investigative Site #601 - CABA
- Climb Bio Investigative Site #604 - CABA
- Climb Bio Investigative Site #605 - Córdoba
- Climb Bio Investigative Site #606 - Santa Fe
- Climb Bio Investigative Site #502 - Belo Horizonte
- Climb Bio Investigative Site #505 - Minas Gerais
- Climb Bio Investigative Site #506 - Pernambuco
- Climb Bio Investigative Site #501 - Porto Alegre
- Climb Bio Investigative Site #503 - São Paulo
- Climb Bio Investigative Site #504 - São Paulo
Texas
- Climb Bio Investigative Site #103 - El Paso
- Climb Bio Investigative Site #104 - Sherman
Colorado
- Climb Bio Investigative Site #110 - Denver
Florida
- Climb Bio Investigative Site #105 - Orlando
Georgia
- Climb Bio Investigative Site #108 - Atlanta
Indiana
- Climb Bio Investigative Site #106 - Indianapolis
New York
- Climb Bio Investigative Site #101 - Clifton Park
Pennsylvania
- Climb Bio Investigative Site #102 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07096843
The ClinicalTrials.gov registry entry for NCT07096843 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (66% lower). The listed sponsor is Climb Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which budoprutug is the first listed.
NCT07096843 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT07096843 about?
NCT07096843 is a clinical study titled "A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy". To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
What is the current status of trial NCT07096843?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-08-25. Estimated completion is 2027-10.
What conditions does trial NCT07096843 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy.
What interventions are being tested in trial NCT07096843?
The interventions under investigation include: budoprutug (DRUG).
Who is sponsoring clinical trial NCT07096843?
This trial is sponsored by Climb Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096843 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RECRUITING · Phase 2
-
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 3
-
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.